|
Patient number
|
Age (years)
|
Origin
|
Gleason score
|
% Invasion in vitro*
|
|---|
|
228
|
-
|
LN metastasis
|
7
|
101 ± 21
|
|
434
|
59
|
Prostate
|
8/9
|
99 ± 56
|
|
484
|
69
|
Prostate
|
7
|
105 ± 29
|
|
512
|
74
|
Prostate
|
BPH
|
-
|
|
561
|
72
|
Prostate
|
BPH
|
-
|
|
563
|
64
|
Prostate
|
7
|
35 ± 9.5
|
|
569
|
64
|
Prostate
|
8
|
75 ± 9
|
|
574
|
74
|
Prostate
|
BPH/G6 (5%)
|
-
|
|
605
|
56
|
LN metastasis
|
7
|
119 ± 21
|
|
661
|
78
|
Prostate
|
6
|
-
|
|
627
|
79
|
Prostate
|
BPH
|
-
|
|
662
|
66
|
Prostate
|
BPH
|
-
|
|
665
|
53
|
Prostate
|
7
|
63 ± 18.4
|
|
667
|
47
|
Prostate
|
6
|
61 ± 4.2
|
|
687
|
63
|
Prostate
|
7
|
74
|
|
690
|
79
|
Prostate
|
BPH
|
-
|
|
693
|
75
|
Prostate
|
BPH
|
-
|
|
704
|
64
|
Prostate
|
7 (HR)
|
-
|
|
003/06
|
52
|
Prostate
|
6
|
-
|
- *Invasion assays were carried out on total epithelial cell populations before fractionation according to [4]. Positive controls for invasive capacity were cell lines MCF7 and PC3M whose invasion score was 18-36%, whereas normal cell lines PNT2 and PNT1a and BPH/primary normal prostate invasion scores ranged from 3-6%. Patient 704 was being treated (hormone refractory (HR)) by androgen blockade therapy.
